Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02279888 · ClinicalTrials.gov registry record
CardioMEMS HF System Post Approval Study
A clinical trial of Heart Failure and Congestive Heart Failure, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 1,214
- Enrollment target
- 1
- Study location
NCT02279888 is a study of Heart Failure and Congestive Heart Failure that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,214 participants, below the 2,046-participant average among 397 other Heart Failure trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02279888, a study of Heart Failure and Congestive Heart Failure, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 1,214 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the CardioMEMS HF System Post Approval Study (PAS) is to evaluate the use of the CardioMEMS HF System in patients with NYHA class III heart failure in a commercial setting.
Conditions Studied
Interventions
- DEVICE CardioMEMS HF System
Study Locations (1)
West Virginia
- West Virginia Heart Institute - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,214 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-10-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02279888
The ClinicalTrials.gov registry entry for NCT02279888 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,214 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,046-participant average among 397 other Heart Failure trials with a reported enrollment target (41% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which CardioMEMS HF System is the first listed.
NCT02279888 reports 1 study location spanning 1 distinct geographic area - top geographies include West Virginia.
Frequently Asked Questions
What is clinical trial NCT02279888 about?
NCT02279888 is a clinical study titled "CardioMEMS HF System Post Approval Study". The purpose of the CardioMEMS HF System Post Approval Study (PAS) is to evaluate the use of the CardioMEMS HF System in patients with NYHA class III heart failure in a commercial setting.
What is the current status of trial NCT02279888?
This trial is currently completed. The enrollment target is 1,214 participants. The study started on 2015-01. Estimated completion is 2019-10-11.
What conditions does trial NCT02279888 study?
This clinical trial studies the following conditions: Heart Failure, Congestive Heart Failure, Left-Sided Heart Failure.
What interventions are being tested in trial NCT02279888?
The interventions under investigation include: CardioMEMS HF System (DEVICE).
Who is sponsoring clinical trial NCT02279888?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02279888 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.